Salud financiera de hoja de balance de GoHealth

Salud financiera controles de criterios 3/6

GoHealth tiene un patrimonio de los accionistas total de $378.9M y una deuda total de $453.3M, lo que sitúa su ratio deuda-patrimonio en 119.6%. Sus activos y pasivos totales son $1.3B y $878.2M respectivamente.

Información clave

119.6%

Ratio deuda-patrimonio

US$453.33m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$14.12m
Patrimonio	US$378.90m
Total pasivo	US$878.18m
Activos totales	US$1.26b

Actualizaciones recientes sobre salud financiera

Recent updates

GoHealth: Turning The Corner On Operating Cash Flow

May 28

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($301.2M) de GOCO superan a sus pasivos a corto plazo ($234.0M).

Pasivo a largo plazo: Los activos a corto plazo ($301.2M) de GOCO no cubren sus pasivos a largo plazo ($644.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de GOCO (115.9%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de GOCO ha crecido de 44.1% a 119.6% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable GOCO tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: GOCO no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 17.6% al año.

Salud financiera de hoja de balance de GoHealth

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

GoHealth, Inc. Receives Extension Notice from Nasdaq

GoHealth, Inc. announced delayed 10-Q filing

GoHealth, Inc. announced delayed annual 10-K filing

Recent updates

GoHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

New minor risk - Shareholder dilution

GoHealth, Inc. Appoints Brendan Shanahan as Chief Financial Officer, Effective October 14, 2024

GoHealth, Inc. (NasdaqCM:GOCO) completed the acquisition of e-TeleQuote Insurance, Inc.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

GoHealth, Inc. (NasdaqCM:GOCO) entered into a purchase agreement to acquire e-TeleQuote Insurance, Inc.

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

GoHealth, Inc. Provides Earnings Guidance for the Full Year 2024

New minor risk - Share price stability

GoHealth, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Shareholder dilution

Less than half of directors are independent

GoHealth, Inc. Announces Changes to Board of Directors

New minor risk - Shareholder dilution

New minor risk - Share price stability

New minor risk - Market cap size

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth: Turning The Corner On Operating Cash Flow

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.12 loss in 1Q 2023)

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 18%

Robbins Geller Rudman & Dowd LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the GoHealth, Inc. Securities Litigation

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Price target increased by 43% to US$20.00

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Group of buyers cancelled the acquisition of remaining stake in GoHealth, Inc. (NasdaqCM:GOCO).

GoHealth, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GoHealth, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 17%

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Price target increased by 31% to US$14.02

Group of buyers submitted a non-binding proposal to acquire remaining stake in GoHealth, Inc. (NasdaqCM:GOCO) for approximately $330 million.

CEO & Director recently bought US$100k worth of stock

Consensus EPS estimates upgraded to US$3.74 loss

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GoHealth, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus revenue estimates decrease by 15%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 34%

Consensus EPS estimates fall by 37%

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Consensus forecasts updated

GoHealth, Inc. Receives Extension Notice from Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

GoHealth, Inc. to Report Q3, 2022 Results on Nov 10, 2022

GoHealth stock jumps 11% premarket on $50M private investment

GoHealth, Inc. announced delayed 10-Q filing

Price target decreased to US$1.10

GoHealth, Inc. to Report Q2, 2022 Results on Aug 15, 2022

GoHealth, Inc. Appoints Shane Cruz as Chief Strategy Officer

GoHealth, Inc. Names Jason Schulz as Chief Financial Officer

High number of new and inexperienced directors

GoHealth, Inc. Announces Executive Changes

GoHealth, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

GoHealth, Inc., Annual General Meeting, May 25, 2022

GoHealth, Inc. Announces the Resignation of Anita Pramoda from the Board of Directors

GoHealth, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 68%

GoHealth, Inc. Provides Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021

Price target decreased to US$4.25

GoHealth: Painful Competition, Cost Controls Are Key

Price target decreased to US$5.79